株式会社マトリクソーム

Matricome develops regenerative medicines by disseminating laminin E8 fragment technology.

Based based in Tokyo, Japan, 株式会社マトリクソーム works in medtech.

Profile

"Matricome is a Medtech company focused on developing regenerative medicines through the dissemination of laminin E8 fragment technology. Based on a novel concept that highlights the interaction between cells and the extracellular environment, Matricome offers a diverse range of products, including iMatrix, utilized in fields such as regenerative medicine and cell culture. Developed through collaborative research with Osaka University, iMatrix plays a crucial role in advanced treatments like Laminin Cornea Transplant. Matricome continues to innovate by developing new products like iMatrix-Palette and providing cutting-edge technology for research and development in areas such as cardiac cell studies. By delivering innovative solutions in regenerative medicine and cell therapy, Matricome contributes to advancements in healthcare."

Its activity falls under medtech; the profile below is assembled from public directory data.

The business is associated with Tokyo, Japan.

Directory data places it at the Plug and Play portfolio startup stage.

Website: www.matrixome.co.jp